Committee split over KPV after FDA warns of inconsistent naming and missing quality data

FDA staff presented the committee with a technical finding: nominations for KPV used a common name and in some submissions COAs referenced different chemical forms, making it unclear whether the nominated bulk drug substance was the free base or an acetate salt. "Because the information provided in the nomination package was inconsistent, it's unclear which KPV‑related BDS was intended for nomination," said chemistry reviewer Jing Li.

The public hearing produced sharply divided views. Clinicians and compounding advocates argued KPV is a small tripeptide with low theoretical immunogenicity that clinicians have used under supervision. "KPV is probably the easiest to understand of all these peptides," said Dr. Matt Cook, who described large clinical experience in private practice. By contrast, public‑interest groups and several FDA reviewers emphasized the absence of published human studies, lack of COAs that list individual impurities and aggregate testing results, and the need for controlled evidence before broad compounding use.

The committee held advisory votes on KPV free base and KPV acetate; members offered a range of rationales—several supported limited, topical or transmucosal access with enhanced supplier controls and third‑party lot testing, while others said they could not recommend listing without better characterization and human safety data. FDA staff reminded members that any final change to the bulks list requires notice‑and‑comment rulemaking and that the agency will consider all docket comments and post‑hearing submissions before issuing a final rule.

The exchange underscored two recurrent themes at the meeting: FDA's technical emphasis on precise chemical identity and laboratory test panels for peptides intended for parenteral use, and public testimony that large existing online use argues for bringing products into a regulated health‑care pathway rather than leaving patients to the gray market.